Servier and other global drugmakers to optimize their Russian range

1 July 2019

Global drugmakers operating in the Russian market are considering optimizing of their local ranges this year, mainly as a result of the introduction of new labeling practices in Russia, starting from January, 1 2020, and with the associated increase of their costs, reports The Pharma Letter’s local correspondent.

For example, French drugmaker Servier, in a letter dated June 21, informed its Russian partners about the termination of imports and manufacture of certain drugs from its Russian range this year.

According to the company, the supplies of these drugs will continue, but will be offered in another packaging form.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK